Reading Time: 6 minutesOver the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.
Category: Clinical Trials
Reading Time: 5 minutesThe top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium
Reading Time: 2 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 2 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 6 minutesOn 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Reading Time: 5 minutesIn this guest blog written by Harry Bowles and Sarah Opie-Martin from King’s College London they discuss their MND research poster which was presented at
Reading Time: 6 minutesUpdate 21/09/2022: The results of the VALOR trial and its open label extension were published in the New England Journal of Medicine. These results give
Reading Time: 6 minutesThis year is set to be an exciting time for MND research, and we are especially hopeful that MND clinical trials will take centre stage